Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
A Houston-area company has just inked a massive, $1 billion deal to become the next big weight-loss medication maker. The timeline for the company to begin receiving payments is dependent on the ...
MedPage Today on MSN6d
STRIDE: Semaglutide Shows It Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback